Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved in pain signaling.

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...

Vertex Pharmaceuticals ... Wall Street analysts expect that Journavx, whose active ingredient is suzetrigine, could bring in about $100 million in sales this year. “We believe the opioid ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.

While it's next to impossible to know how many opioids entered the state illegally in 2023, we do know that just under 1.7 ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...